Efficacy and Safety of Extended Release (ER) Niacin/Laropiprant When Added to Ongoing Lipid-Modifying Therapy in Patients With High Cholesterol or Abnormal Lipid Levels (MK-0524A-133)

A phase 3 trial registered on ClinicalTrials.gov. The registry status is terminated. It enrolled 1173 participants.

Also called NCT01274559

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 1,173 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT01274559
  • CTRI CTRI/2012/08/002857
  • EudraCT 2010-021627-27
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
Not reported
Registry status
  • Terminated (from the registry)

Technical summary

Registry record NCT01274559. Randomized; double masking; primary purpose treatment. Start 2011-03-01 (actual); primary completion 2013-02-26 (actual). Results posted on 2014-03-14.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Efficacy and Safety of Extended Release (ER) Niacin/Laropiprant When Added to Ongoing Lipid-Modifying Therapy in Patients With High Cholesterol or Abnormal Lipid Levels (MK-0524A-133)
Condition
Primary Hypercholesterolemia
Condition
Mixed Dyslipidemia
Intervention (Drug)
Extended-release niacin/laropiprant (ERN/LRPT)
Intervention (Drug)
Placebo
Lead sponsor
Merck Sharp & Dohme LLC (class: industry)

Record details

Record id
cardio:ct-nct01274559
Content hash
871e643062f575c8584c54293be3a2af74c78eca7e34620c98b273c63dcd4f25